benzyl N-[5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate | 262430-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: benzyl N-[5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate
• 英文别名: benzyl N-[5-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate
• CAS: 262430-24-0
• 化学式: C₂₆H₂₇N₅O₃
• 分子量: 457.532
• InChiKey: QHNYMTOVBIEZFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-(3-amino-4-methoxyphenyl)-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 、 氯甲酸苄酯 以 二氯甲烷 、 吡啶 为溶剂， 反应 1.0h， 以then lyophilization provided benzyl N-[5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (25 mg) as a white powder的产率得到benzyl N-[5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate
  参考文献：
  名称：

  4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS

  摘要：

  结构式I1及其生理可接受的盐是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物所抑制的多种激酶参与免疫、增殖或血管生成过程。因此，这些化合物可改善血管生成或内皮细胞增殖是疾病状态。这些化合物可用于治疗癌症、增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。

  公开号：

  US20030187001A1

文献信息

• Method of treating transplant rejection
  申请人：Waegell Wendy

  公开号：US20050008640A1

  公开（公告）日：2005-01-13

  This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.

  本发明涉及一种治疗移植排斥的方法，包括向患者施用一种药物组合物，该药物组合物包括lck抑制剂和钙调蛋白酶抑制剂或免疫抑制剂。
• 4-aminopyrrolopyrimidines as kinase inhibitors
  申请人：Abbott Laboratories

  公开号：US07863444B2

  公开（公告）日：2011-01-04

  Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

  具有结构式I及其生理可接受的盐的化合物是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的多种激酶参与免疫、过度增殖或血管生成过程。因此，这些化合物可改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症、过度增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• US7863444B2
  申请人：——

  公开号：US7863444B2

  公开（公告）日：2011-01-04
• [EN] 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] 4-AMINOPYRROLOPYRIMIDINES UTILISEES COMME INHIBITEURS DE KINASES
  申请人：BASF AG

  公开号：WO2000017202A1

  公开（公告）日：2000-03-30

  Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
• [EN] METHOD OF TREATING TRANSPLANT REJECTION<br/>[FR] PROCEDE SERVANT A TRAITER LE REJET D'UN TRANSPLANT
  申请人：ABBOTT LAB

  公开号：WO2004100868A2

  公开（公告）日：2004-11-25

  This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.